WO1987001132A1 - Production of pluripotent granulocyte colony-stimulating factor - Google Patents
Production of pluripotent granulocyte colony-stimulating factor Download PDFInfo
- Publication number
- WO1987001132A1 WO1987001132A1 PCT/US1986/001708 US8601708W WO8701132A1 WO 1987001132 A1 WO1987001132 A1 WO 1987001132A1 US 8601708 W US8601708 W US 8601708W WO 8701132 A1 WO8701132 A1 WO 8701132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- hpg
- dna sequence
- polypeptide
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR870700352A KR880700071A (en) | 1985-08-23 | 1986-08-22 | Production of Pluripotent Granulocyte Colony-stimulating Factors |
DE8686905530T DE3679397D1 (en) | 1985-08-23 | 1986-08-22 | PRODUCTION OF PLURIPOTENT GRANULOCYT COLONIZING FACTOR. |
AT86905530T ATE63758T1 (en) | 1985-08-23 | 1986-08-22 | PRODUCTION OF PLURIPOTENTS GRANULOCYTE COLONY EXCITING FACTOR. |
EP86905530A EP0237545B2 (en) | 1985-08-23 | 1986-08-22 | Production of pluripotent granulocyte colony-stimulating factor |
FI871700A FI105191B (en) | 1985-08-23 | 1987-04-16 | A method for producing a multifunctional granulocyte colony stimulating factor encoding a DNA sequence; vector and host cell |
DK198702044A DK174980B1 (en) | 1985-08-23 | 1987-04-22 | Isolated polypeptide having properties such as hpG-CSF, DNA sequence encoding it, plasmids containing the sequence, transformed / transfected host cells, method for producing the polypeptide, pharmaceutical composition containing it ... |
NO871679A NO303544B1 (en) | 1985-08-23 | 1987-04-22 | Method for Preparation of a Polypeptide having One or More of the Hematopoietic Biological Properties of Granulocyte Colony Stimulating Factor (hpG-CSF) |
SG358/92A SG35892G (en) | 1985-08-23 | 1992-03-26 | Production of pluripotent granulocyte colony-stimulating factor |
HK71892A HK71892A (en) | 1985-08-23 | 1992-09-17 | Production of pluripotent granulocyte colony-stimulating factor |
NL930127C NL930127I1 (en) | 1985-08-23 | 1993-07-01 | Formation of a multi-active granulocyte colony stimulating factor |
NO954199A NO954199D0 (en) | 1985-08-23 | 1995-10-20 | DNA sequence encoding a polypeptide product |
NO19982132A NO314902B1 (en) | 1985-08-23 | 1998-05-11 | Biologically functional plasmid or viral DNA vector encoding an analog of granulocyte colony stimulating factor (hpG-CSF), co-prokaryotic or eukaryotic host cell |
FI20000014A FI107540B (en) | 1985-08-23 | 2000-01-04 | Pluripotent granulocyte colony-stimulating factor |
FI20010334A FI110576B (en) | 1985-08-23 | 2001-02-21 | Process for Preparation of a Human Pluripotent Granulocyte Colon Stimulating Factor (hpG-CSF) Product |
NO20032250A NO318755B1 (en) | 1985-08-23 | 2003-05-19 | Use of a hpG-CSF polypeptide for the preparation of a drug for stopping the proliferation of leukemia cells |
NO2003008C NO2003008I1 (en) | 1985-08-23 | 2003-11-13 | Procedure for Preparation of a Polypeptide with One or More of the Hematopoietic Biological Properties of the Gluenocyte Colony Stimulating Factor (hpg-csf) |
NO2003010C NO2003010I2 (en) | 1985-08-23 | 2003-12-09 | pegfilgrastim |
NO20045548A NO20045548L (en) | 1985-08-23 | 2004-12-17 | Process for the preparation of a hpG-CSF polypeptide product, and its use for the preparation of a medicament for inducing the proliferation of human bone marrow cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76895985A | 1985-08-23 | 1985-08-23 | |
US768,959 | 1985-08-23 | ||
US06/835,548 US4810643A (en) | 1985-08-23 | 1986-03-03 | Production of pluripotent granulocyte colony-stimulating factor |
US835,548 | 1986-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1987001132A1 true WO1987001132A1 (en) | 1987-02-26 |
Family
ID=27118107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1986/001708 WO1987001132A1 (en) | 1985-08-23 | 1986-08-22 | Production of pluripotent granulocyte colony-stimulating factor |
Country Status (24)
Country | Link |
---|---|
US (5) | US4810643A (en) |
EP (1) | EP0237545B2 (en) |
JP (11) | JP2527365B2 (en) |
KR (1) | KR880700071A (en) |
CN (1) | CN1020924C (en) |
AT (1) | ATE332375T1 (en) |
AU (1) | AU6334686A (en) |
CA (1) | CA1341537C (en) |
CY (1) | CY1642A (en) |
DE (1) | DE3650788T2 (en) |
DK (1) | DK174980B1 (en) |
ES (1) | ES2001883A6 (en) |
FI (3) | FI105191B (en) |
GR (1) | GR862185B (en) |
HK (1) | HK1029600A1 (en) |
IL (1) | IL79805A (en) |
MX (1) | MX9202992A (en) |
NL (1) | NL930127I1 (en) |
NO (6) | NO303544B1 (en) |
NZ (1) | NZ217334A (en) |
PT (1) | PT83242B (en) |
SA (1) | SA92130186B1 (en) |
SG (2) | SG48964A1 (en) |
WO (1) | WO1987001132A1 (en) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215126A1 (en) * | 1985-02-08 | 1987-03-25 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
EP0243153A2 (en) * | 1986-04-22 | 1987-10-28 | Immunex Corporation | Human G-CSF protein expression |
EP0256843A1 (en) * | 1986-08-11 | 1988-02-24 | Cetus Corporation | Expression of g-csf and muteins thereof and their use |
EP0272703A1 (en) | 1986-12-23 | 1988-06-29 | Kyowa Hakko Kogyo Co., Ltd. | Novel polypeptide |
GB2213821A (en) * | 1987-12-23 | 1989-08-23 | British Bio Technology | Synthetic gene |
EP0331186A2 (en) * | 1988-03-04 | 1989-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Monoclonal antibody selectively binding to novel g-csf derivative |
EP0422872A2 (en) * | 1989-10-12 | 1991-04-17 | Gene-Trak Systems | Nucleic acid probes and methods for detecting fungi |
US5194592A (en) * | 1986-12-23 | 1993-03-16 | Kyowa Hakko Kogyo Co. Ltd. | Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor |
US5214132A (en) * | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
WO1994017185A1 (en) * | 1993-01-28 | 1994-08-04 | Amgen Inc. | G-csf analog compositions and methods |
EP0719860A1 (en) * | 1988-05-13 | 1996-07-03 | Amgen Inc. | Compositions and method for treating or preventing infections in animals |
US5599690A (en) * | 1988-02-01 | 1997-02-04 | Amgen Inc. | Control of norleucine incorporation into recombinant proteins |
WO2002066051A1 (en) | 2001-02-22 | 2002-08-29 | Didier Pourquier | Use of the g-csf as adjuvant treatment in connective tissue recontruction |
WO2004001056A1 (en) * | 2002-06-24 | 2003-12-31 | Dr. Reddy's Laboratories Ltd. | Process for preparing g-csf |
US6956027B2 (en) | 1994-10-12 | 2005-10-18 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US7090835B2 (en) | 1994-10-12 | 2006-08-15 | Amgen, Inc. | N-terminally chemically modified protein compositions and methods |
WO2008096370A2 (en) * | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
DE202007018618U1 (en) | 2006-03-01 | 2008-12-11 | Bioceuticals Arzneimittel Ag | G-CSF liquid formulation |
EP2058326A1 (en) | 2005-07-15 | 2009-05-13 | Bioceuticals Arzneimittel AG | Method for the purificaiton of G-CSF |
DE202008017456U1 (en) | 2007-08-27 | 2009-08-27 | Biogenerix Ag | Liquid formulation of G-CSF conjugates |
US7655766B2 (en) | 2005-06-01 | 2010-02-02 | Carsten Germansen | Compositions comprising positional isomers of PEGylated G-CSF |
US7696153B2 (en) | 2000-01-10 | 2010-04-13 | Maxygen, Inc. | G-CSF conjugates |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
EP2186525A2 (en) | 2002-12-31 | 2010-05-19 | SYGNIS Bioscience GmbH & Co KG | G-CSF for use in the treatment of Parkinson's disease |
US7959909B2 (en) | 1997-07-14 | 2011-06-14 | Bolder Biotechnology, Inc. | Cysteine variants of interferon gamma |
EP2341061A1 (en) | 2009-12-31 | 2011-07-06 | Sanovel Ilac Sanayi ve Ticaret A.S. | A novel process for preparing G-CSF (granulocyte colony stimulating factor) |
AU2011201971B2 (en) * | 1993-01-28 | 2011-12-01 | Amgen Inc. | G-CSF analog compositions |
US8101188B2 (en) | 1997-10-02 | 2012-01-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
US8133480B2 (en) | 1997-07-14 | 2012-03-13 | Bolder Biotechnology, Inc. | Cysteine variants of interleukin-11 |
US8148500B2 (en) | 1997-07-14 | 2012-04-03 | Bolder Biotechnology, Inc. | Method of preparing cysteine mutants of human recombinant GM-CSF |
WO2013068602A2 (en) | 2012-03-19 | 2013-05-16 | Richter Gedeon Nyrt. | Method for the production of polypeptides |
WO2013068603A2 (en) * | 2012-03-19 | 2013-05-16 | Richter Gedeon Nyrt. | Methods for refolding g-csf from inclusion bodies |
US8562967B2 (en) | 2007-08-27 | 2013-10-22 | Biogenerix Ag | Stable liquid formulations of G-CSF |
US8859497B2 (en) | 1997-07-14 | 2014-10-14 | Bolder Biotechnology, Inc. | Method of treatment using cysteine mutants of beta interferon |
US8871439B2 (en) | 2005-06-30 | 2014-10-28 | Octapharma Ag | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US8957023B2 (en) | 1999-01-14 | 2015-02-17 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
US9155780B2 (en) | 2009-02-11 | 2015-10-13 | Yeda Research And Development Co. Ltd. | Short beta-defensin-derived peptides |
EP3070099A1 (en) | 2015-03-16 | 2016-09-21 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for preparing granulocyte colony stimulating factor (g-csf) |
WO2017067958A1 (en) * | 2015-10-19 | 2017-04-27 | Sandoz Ag | Improved coding sequence for human g-csf |
EP3578205A1 (en) * | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
Families Citing this family (297)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU594014B2 (en) * | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
US5718893A (en) * | 1984-04-15 | 1998-02-17 | Foster; Preston F. | Use of G-CSF to reduce acute rejection |
US5532341A (en) * | 1985-03-28 | 1996-07-02 | Sloan-Kettering Institute For Cancer Research | Human pluripotent hematopoietic colony stimulating factor |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US6004548A (en) * | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
NZ218336A (en) * | 1985-12-09 | 1991-08-27 | Kirin Amgen Inc | Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf) |
GR871067B (en) * | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
US5186931A (en) * | 1986-08-06 | 1993-02-16 | Ajinomoto Co., Inc. | Composition and method for supporting bone marrow transplantation |
JPH0618781B2 (en) * | 1986-10-18 | 1994-03-16 | 中外製薬株式会社 | Infectious disease treatment agent |
US6238889B1 (en) * | 1986-12-16 | 2001-05-29 | Dsm N.V. | Molecular cloning and expression of the Pro8 isoform of human IL-3 |
US5681720A (en) * | 1986-12-23 | 1997-10-28 | Kyowa Hakko Co., Ltd. | DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide |
US5362853A (en) * | 1986-12-23 | 1994-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US6384194B1 (en) * | 1987-12-16 | 2002-05-07 | Dsm N.V. | Expression and purification of human interleukin-3 and muteins thereof |
CA1329119C (en) * | 1988-03-29 | 1994-05-03 | Milton David Goldenberg | Cytotoxic therapy |
US20030232010A2 (en) * | 1988-03-29 | 2003-12-18 | Immunomedics, Inc. | Improved cytotoxic therapy |
US5070013A (en) * | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
US5082774A (en) * | 1988-08-30 | 1992-01-21 | The General Hospital Corporation | Recombinant human nerve growth factor |
US5218092A (en) * | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
DE68925966T2 (en) * | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US6166183A (en) * | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
WO1990012877A1 (en) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
US6254861B1 (en) * | 1989-05-23 | 2001-07-03 | Chandra Choudhury | Hematopoietic growth factor derived from T lymphocytes |
US5635386A (en) | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
CA2062741A1 (en) * | 1989-06-15 | 1990-12-16 | Stephen G. Emerson | Methods, compositions and devices for growing cells |
US5605822A (en) * | 1989-06-15 | 1997-02-25 | The Regents Of The University Of Michigan | Methods, compositions and devices for growing human hematopoietic cells |
US5763266A (en) * | 1989-06-15 | 1998-06-09 | The Regents Of The University Of Michigan | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells |
US5665543A (en) * | 1989-07-18 | 1997-09-09 | Oncogene Science, Inc. | Method of discovering chemicals capable of functioning as gene expression modulators |
US5776502A (en) | 1989-07-18 | 1998-07-07 | Oncogene Science, Inc. | Methods of transcriptionally modulating gene expression |
US6203976B1 (en) | 1989-07-18 | 2001-03-20 | Osi Pharmaceuticals, Inc. | Methods of preparing compositions comprising chemicals capable of transcriptional modulation |
US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
AU641949B2 (en) * | 1989-10-10 | 1993-10-07 | Amgen, Inc. | Compositions and methods for treating or preventing infections in canine and feline animals |
US7144731B2 (en) | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
US6852313B1 (en) | 1989-10-16 | 2005-02-08 | Amgen Inc. | Method of stimulating growth of melanocyte cells by administering stem cell factor |
EP0676470A1 (en) * | 1989-10-16 | 1995-10-11 | Amgen Inc. | Stem cell factor |
US20040181044A1 (en) * | 1989-10-16 | 2004-09-16 | Zsebo Krisztina M. | Method of stimulating growth of epithelial cells by administering stem cell factor |
GEP20002145B (en) * | 1989-10-16 | 2000-06-25 | Amgen Inc Us | Stem Cell Factor |
ZA907921B (en) | 1989-10-16 | 1991-08-28 | Amgen Inc | Stem cell factor |
US5214133A (en) * | 1989-11-17 | 1993-05-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SCL: a hematopoietic growth and differentiation factor |
US5132212A (en) * | 1989-11-17 | 1992-07-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Scl gene, and a hematopoietic growth and differentiation factor encoded thereby |
JPH04218000A (en) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | Modified polypeptide |
US5147799A (en) * | 1990-04-25 | 1992-09-15 | Isia Bursuker | Repopulation of macrophages and granulocytes using transforming growth factor-beta |
GB9107846D0 (en) * | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
US5399345A (en) * | 1990-05-08 | 1995-03-21 | Boehringer Mannheim, Gmbh | Muteins of the granulocyte colony stimulating factor |
US5258367A (en) * | 1990-06-29 | 1993-11-02 | University Of Florida | Uteroferrin and rose proteins for stimulating hematopoietic cells |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
JPH05506673A (en) * | 1991-02-22 | 1993-09-30 | アムジエン・インコーポレーテツド | Use of GM-CSF and G-CSF to promote rapid wound healing |
GB2253852B (en) * | 1991-02-26 | 1995-03-22 | Ici Plc | Vector for expression of heterologous polypeptide comprising inducible selection system |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6153183A (en) * | 1992-11-24 | 2000-11-28 | G. D. Searle & Company | Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production |
US6413509B1 (en) | 1992-11-24 | 2002-07-02 | S. Christopher Bauer | Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors |
US6361977B1 (en) | 1992-11-24 | 2002-03-26 | S. Christopher Bauer | Methods of using multivariant IL-3 hematopoiesis fusion protein |
US6403076B1 (en) | 1992-11-24 | 2002-06-11 | S. Christopher Bauer | Compositions for increasing hematopoiesis with interleukin-3 mutants |
US5772992A (en) * | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US6361976B1 (en) | 1992-11-24 | 2002-03-26 | S. Christopher Bauer | Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production |
US6057133A (en) * | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
US7091319B1 (en) | 1992-11-24 | 2006-08-15 | Bauer S Christopher | IL-3 variant hematopoiesis fusion protein |
CA2523216C (en) | 1993-09-15 | 2010-11-16 | Chiron Corporation | Recombinant alphavirus vectors |
US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US20050059149A1 (en) * | 1993-11-22 | 2005-03-17 | Bauer S. Christopher | Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins |
CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
US6242417B1 (en) | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
US5766581A (en) * | 1994-03-31 | 1998-06-16 | Amgen Inc. | Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation |
US5536495A (en) * | 1994-04-15 | 1996-07-16 | Foster; Preston F. | Use of G-CSF to reduce acute rejection |
US6100070A (en) * | 1995-10-05 | 2000-08-08 | G. D. Searle & Co. | G-CSF receptor agonists |
US6066318A (en) * | 1995-10-05 | 2000-05-23 | G.D. Searle & Co. | Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors |
DE69738521T2 (en) | 1996-04-05 | 2009-05-07 | Novartis Vaccines and Diagnostics, Inc., Emeryville | ALPHAVIRUS VECTORS WITH A REDUCED INHIBITION OF THE SYNTHESIS OF CELL MACROMOLECULES |
JP2001500738A (en) | 1996-09-17 | 2001-01-23 | カイロン コーポレイション | Compositions and methods for treating intracellular diseases |
US6162426A (en) * | 1997-05-05 | 2000-12-19 | La Gamma; Edmund F. | Use of G-CSF to enhance the immune system in neonates |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
US20020034819A1 (en) * | 1998-02-23 | 2002-03-21 | Alan K. Smith | Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
CN1101403C (en) * | 1998-07-13 | 2003-02-12 | 金磊 | Preparation of granulocyte colony stimulation factor |
US6979442B1 (en) | 1998-08-17 | 2005-12-27 | Pfizer Inc. | Stabilized protein compositions |
US5999474A (en) | 1998-10-01 | 1999-12-07 | Monolithic System Tech Inc | Method and apparatus for complete hiding of the refresh of a semiconductor memory |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
CA2360347C (en) | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US7208473B2 (en) * | 1999-01-06 | 2007-04-24 | Xencor, Inc. | Nucleic acids and protein variants of hG-CSF with granulopoietic activity |
JP4092081B2 (en) | 1999-01-06 | 2008-05-28 | ゼンコー・インコーポレイテッド | G-CSF variant equivalent nucleic acid and protein having granulocyte forming activity |
WO2000041514A2 (en) | 1999-01-19 | 2000-07-20 | Biostream, Inc. | Conjugates of colony stimulating factors for targeting and imaging infection and inflammation |
ES2204509T3 (en) * | 1999-01-29 | 2004-05-01 | F. Hoffmann-La Roche Ag | CONJUGATES OF GCSF. |
US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
KR100356140B1 (en) * | 1999-07-08 | 2002-10-19 | 한미약품공업 주식회사 | Modified Human Granulocyte-Colony Stimulating Factor and Process for Producing Same |
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
EP2292657A1 (en) | 1999-11-12 | 2011-03-09 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
US6646110B2 (en) | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
ES2327606T3 (en) | 2000-01-10 | 2009-11-02 | Maxygen Holdings Ltd | CONJUGATES OF G-CSF. |
US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
CA2337661A1 (en) | 2000-02-29 | 2001-08-29 | Pfizer Products Inc. | Stabilized granulocyte colony stimulating factor |
CN1420776A (en) * | 2000-03-31 | 2003-05-28 | 塞尔基因公司 | Inhibition of cyclooxygenase-2 activity |
EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
US6946548B2 (en) * | 2000-09-08 | 2005-09-20 | Massachusetts Institute Of Technology | G-CSF analog compositions and methods |
US20020150979A1 (en) * | 2000-10-04 | 2002-10-17 | Naokazu Naitou | Process for producing a protein |
ES2290091T3 (en) * | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | SYNTHESIS OF ENANTIOMERS OF 4-AMINO-TALIDOMIDE. |
EP1229045A1 (en) | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
EP1998266A3 (en) | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
US6956023B1 (en) | 2001-04-19 | 2005-10-18 | University Of Florida | Materials and methods for providing nutrition to neonates |
JP5033303B2 (en) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Polynucleotides encoding polypeptides with antigenic type C HIV, polypeptides and uses thereof |
US20030198621A1 (en) | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
MXPA04000982A (en) * | 2001-07-31 | 2004-04-20 | Anormed Inc | Methods to mobilize progenitor/stem cells. |
US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
NZ532027A (en) | 2001-10-10 | 2008-09-26 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
CN105131104B (en) | 2001-10-10 | 2018-11-16 | 诺和诺德公司 | The reconstruct and sugar conjugation of peptide |
SI21102A (en) | 2001-12-19 | 2003-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Process for isolation of biologically active granulocyte colony stimulating factor |
EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
KR20030062854A (en) * | 2002-01-21 | 2003-07-28 | 주식회사 엘지생명과학 | Manufacturing method of recombinant protein in yeast by the use of secretory type vector |
WO2003078461A1 (en) * | 2002-03-20 | 2003-09-25 | Biopolymed Inc. | Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
ES2627445T3 (en) | 2002-05-01 | 2017-07-28 | Miltenyi Biotec Technology, Inc. | Lentivirus vector particles resistant to complement inactivation |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
EP1556033A4 (en) * | 2002-05-17 | 2006-05-31 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
EP2915533B1 (en) | 2002-05-17 | 2017-09-13 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7081443B2 (en) * | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
SI21273A (en) * | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Preparation of inclusion bodies with high fraction of properly twisted heterologous protein precursor |
AU2003261723A1 (en) | 2002-08-27 | 2004-03-19 | Takeda Chemical Industries, Ltd. | Cxcr4 antagonist and use thereof |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
AU2003228509B2 (en) * | 2002-10-15 | 2008-06-26 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
BR0316057A (en) | 2002-11-06 | 2005-09-20 | Celgene Corp | Methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis and of reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy or immunotherapy in a patient suffering from a specific cancer, pharmaceutical composition and kit |
KR101042448B1 (en) * | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
BR0317910A (en) * | 2002-12-31 | 2005-11-29 | Axaron Bioscience Ag | Use of a hematopoietic factor; of a polynucleotide encoding said fact; of a neuronal stem cell; and gfc and / or gfc derivatives; methods for identifying a compound; compound thus identified, as well as methods for enhancing the viability of a neural cell culture |
MXPA05008445A (en) * | 2003-02-13 | 2005-10-18 | Anthrogenesis Corp | Use of umbilical cord blood to treat individuals having a disease, disorder or condition. |
ES2436606T3 (en) | 2003-03-12 | 2014-01-03 | Celgene Corporation | 7-amido-isoindolyl compounds and their pharmaceutical uses |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
WO2004091495A2 (en) * | 2003-04-09 | 2004-10-28 | University Of Utah Research Foundation | Compositions and methods related to production of erythropoietin |
US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
US7550484B2 (en) | 2003-04-22 | 2009-06-23 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20070041937A1 (en) * | 2003-08-22 | 2007-02-22 | The Council Of The Queensland Institute Of Medical Research | G-csf derivative for inducing immunological tolerance |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7220407B2 (en) * | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
CN1901911A (en) * | 2003-11-06 | 2007-01-24 | 细胞基因公司 | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
EP1694328A4 (en) * | 2003-12-02 | 2010-02-17 | Celgene Corp | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
WO2005067889A1 (en) | 2003-12-30 | 2005-07-28 | Durect Corporation | Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh |
AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
SE0400942D0 (en) * | 2004-04-08 | 2004-04-08 | Henrik Arnberg | Composition and method |
EP1744749A4 (en) * | 2004-04-14 | 2009-04-22 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
CA2563207A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
EP1586334A1 (en) * | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
WO2006020580A2 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
JP2008509928A (en) * | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | Chemokine combination to mobilize progenitor / stem cells |
US20120225044A9 (en) * | 2004-09-07 | 2012-09-06 | Zymequest, Inc. | Compositions and methods for prolonging survival of platelets |
CA2621250A1 (en) * | 2004-09-07 | 2006-03-16 | Zymequest, Inc. | Apparatus for prolonging survival of platelets |
KR100980693B1 (en) | 2004-09-28 | 2010-09-07 | (주) 에이프로젠 | A Pharmaceutical Composition for Treating Erectile Dysfunction Comprising Chimeric Coiled-Coil Molecule as Active Ingredient |
GB0505353D0 (en) | 2005-03-16 | 2005-04-20 | Chem Technologies Ltd E | Treatment process for concrete |
CN101072585A (en) | 2004-11-01 | 2007-11-14 | 诺华疫苗和诊断公司 | Combination approaches for generating immune responses |
AU2005306894B2 (en) | 2004-11-05 | 2011-11-24 | Northwestern University | Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders |
EP1828241A1 (en) * | 2004-12-23 | 2007-09-05 | Laboratoires Serono S.A. | G-csf polypeptides and uses thereof |
ES2449195T3 (en) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Glycopegylated granulocyte colony stimulating factor |
CA2595695A1 (en) | 2005-01-25 | 2006-08-03 | Cell Therapeutics, Inc. | Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
KR100735784B1 (en) * | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof |
JP2009503111A (en) * | 2005-08-04 | 2009-01-29 | ネクター セラピューティックス エイエル,コーポレイション | G-CSF moiety and polymer composite |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
MX2008010895A (en) * | 2006-02-24 | 2008-09-03 | Genzyme Corp | Methods for increasing blood flow and/or promoting tissue regeneration. |
WO2007102814A2 (en) * | 2006-03-07 | 2007-09-13 | Regenetech, Inc. | Recombinant mammalian molecules and method for production thereof |
GB0605684D0 (en) * | 2006-03-21 | 2006-05-03 | Sicor Biotech Uab | Method For Purifying Granulocyte-Colony Stimulating Factor |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
AU2007258280B2 (en) * | 2006-06-12 | 2013-05-02 | Sunesis Pharmaceuticals, Inc. | Compounds and compositions for treatment of cancer |
MX344865B (en) | 2006-08-02 | 2016-12-19 | Sunesis Pharmaceuticals Inc | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylami no)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-car boxylic. |
CL2007002218A1 (en) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA. |
JP2010507567A (en) * | 2006-08-07 | 2010-03-11 | ジェンザイム・コーポレーション | Combination therapy |
EP3011961B1 (en) | 2006-12-21 | 2020-11-11 | Biokine Therapeutics LTD. | 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation |
WO2008137471A2 (en) * | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
CA2693162C (en) * | 2007-07-17 | 2017-05-16 | Acea Biosciences Inc. | Heterocyclic compounds and uses as anticancer agents |
WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
WO2009023566A2 (en) | 2007-08-09 | 2009-02-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
WO2009046015A2 (en) * | 2007-09-30 | 2009-04-09 | University Of Florida Research Foundation, Inc. | Combination therapies for treating type 1 diabetes |
KR100921226B1 (en) | 2007-10-04 | 2009-10-12 | 학교법인 선목학원 | Retrovirus expression vector containing ??-??? human granulocyte-colony stimulating factor gene and Transgenic poultry thereby |
GB2455204B (en) * | 2007-11-28 | 2010-07-14 | Smart Tube Inc | Devices, systems and methods for the collection, stimulation, stabilization and analysis of a biological sample |
CA2708264C (en) | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
SG188143A1 (en) | 2008-02-08 | 2013-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
CA2722426A1 (en) * | 2008-04-30 | 2009-11-05 | Neutron Row | Methods of using corticotropin-releasing factor for the treatment of cancer |
AU2009246926B2 (en) | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
JP5645816B2 (en) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | Pharmaceutical composition comprising core factor related to proliferation and differentiation of central nerve cell |
MX2011013459A (en) | 2009-06-14 | 2012-05-08 | Biokine Therapeutics Ltd | Peptide therapy for increasing platelet levels. |
SG176963A1 (en) | 2009-06-22 | 2012-02-28 | Amgen Inc | Refolding proteins using a chemically controlled redox state |
JP2012530740A (en) | 2009-06-24 | 2012-12-06 | エヴァンス−フリーク,ステファン | How to use corticotropin-releasing factor for cancer treatment |
EP3660032A1 (en) | 2009-06-25 | 2020-06-03 | Amgen, Inc | Capture purification processes for proteins expressed in a non-mammalian system |
US8470817B2 (en) * | 2009-10-26 | 2013-06-25 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
US20110129858A1 (en) * | 2009-11-27 | 2011-06-02 | Changhua Christian Hospital | Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof |
MX349301B (en) | 2009-12-21 | 2017-07-21 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses. |
BR112012020552A2 (en) | 2010-02-19 | 2016-07-19 | Acea Biosciences Inc | heterocyclic compounds and uses as anticancer agents |
JP5840148B2 (en) * | 2010-03-04 | 2016-01-06 | フェニックス インク. | Method for producing soluble recombinant interferon protein without denaturation |
MX2012010367A (en) | 2010-03-12 | 2012-11-23 | Celgene Corp | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor. |
NZ603033A (en) | 2010-04-01 | 2014-06-27 | Pfenex Inc | Methods for g-csf production in a pseudomonas host cell |
AR083006A1 (en) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME |
ES2641869T3 (en) | 2010-09-28 | 2017-11-14 | Aegerion Pharmaceuticals, Inc. | Leptin-ABD fusion polypeptides with increased duration of action |
WO2012078492A1 (en) | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
WO2012106299A1 (en) | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
SG192946A1 (en) | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
EP2683384B1 (en) | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
US9320777B2 (en) | 2011-05-13 | 2016-04-26 | Bolder Biotechnology, Inc. | Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure |
EP2771296B1 (en) | 2011-10-25 | 2017-09-27 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US10350139B2 (en) | 2011-10-25 | 2019-07-16 | Corning Incorporated | Pharmaceutical glass packaging assuring pharmaceutical sterility |
TWI558401B (en) | 2011-11-01 | 2016-11-21 | 西建公司 | Methods for treating cancers using oral formulations of cytidine analogs |
US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
WO2013155347A1 (en) | 2012-04-11 | 2013-10-17 | Izumi Raquel | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
ES2699810T3 (en) | 2012-06-29 | 2019-02-12 | Celgene Corp | Methods to determine the efficacy of drugs using cereblon-associated proteins |
EP2870238A4 (en) | 2012-07-05 | 2016-03-09 | Ohio State Innovation Foundation | Compositions and methods related to viral vaccines |
WO2014022759A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
SG10201701057SA (en) | 2012-08-09 | 2017-03-30 | Celgene Corp | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
CN104703978B (en) | 2012-08-09 | 2018-05-11 | 细胞基因公司 | Salt and solid form of compound and combinations thereof and application method |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
BR112015005243A2 (en) | 2012-09-10 | 2017-07-04 | Celgene Corp | Methods For Treating Locally Advanced Breast Cancer |
WO2014160698A1 (en) | 2013-03-26 | 2014-10-02 | Celgene Corporation | SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
AU2014248263A1 (en) | 2013-04-02 | 2015-10-15 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US20160122829A1 (en) | 2013-06-06 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using PD-L1 Isoforms |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2015057992A1 (en) | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
EP3068891A1 (en) | 2013-11-13 | 2016-09-21 | Aequus Biopharma Inc. | Engineered glycoproteins and uses thereof |
US20150359810A1 (en) | 2014-06-17 | 2015-12-17 | Celgene Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
ES2843973T3 (en) | 2014-06-27 | 2021-07-21 | Celgene Corp | Compositions and methods to induce conformational changes in cereblon and other E3 ubiquitin ligases |
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
PL3182996T3 (en) | 2014-08-22 | 2023-04-17 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
WO2016167291A1 (en) | 2015-04-13 | 2016-10-20 | 国立研究開発法人産業技術総合研究所 | Cyclized cytokine and method for producing same |
SI3313818T1 (en) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
EP3322431A2 (en) | 2015-07-16 | 2018-05-23 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
WO2017040387A2 (en) | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
US11229683B2 (en) | 2015-09-18 | 2022-01-25 | Bolder Biotechnology, Inc. | Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure |
US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
AU2016342210A1 (en) | 2015-10-19 | 2018-05-10 | Sandoz Ag | Method for producing a recombinant protein with reduced impurities |
EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CN109069486A (en) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | The method for the treatment of cancer |
SI3393468T1 (en) | 2015-12-22 | 2023-01-31 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
SG10202007913WA (en) | 2016-01-08 | 2020-10-29 | Celgene Corp | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
WO2017120422A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Antiproliferative compounds, and their pharmaceutical compositions and uses |
AR107320A1 (en) | 2016-01-08 | 2018-04-18 | Celgene Corp | SOLID FORMS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXOINDOLIN-5-IL) METHYL) -2,2-DIFLUOROACETAMIDE AND ITS PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS |
AU2017222495B2 (en) | 2016-02-23 | 2019-08-08 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
JP2019512271A (en) | 2016-03-21 | 2019-05-16 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | T cell exhaustion state specific gene expression regulator and use thereof |
CN109069512B (en) | 2016-04-01 | 2022-06-14 | 西格诺药品有限公司 | Substituted aminopurine compounds, compositions thereof, and related methods of treatment |
DK3436019T3 (en) | 2016-04-01 | 2021-10-11 | Signal Pharm Llc | (1S, 4S) -4- (2 - (((3S, 4R) -3-FLUORTETRAHYDRO-2H-PYRAN-4-YL) AMINO) -8 - ((2,4,6-TRICHLORPHENYL) AMINO) -9H -PURIN-9-YL) -1-METHYLCYCLOHEXANE-1-CARBOXAMIDE AND METHODS OF USING IT |
JP2019510785A (en) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | How to treat cancer |
JP7250520B2 (en) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | Recombinant arterivirus replicon system and uses thereof |
EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
US10759796B2 (en) | 2016-06-21 | 2020-09-01 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
WO2018013693A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof |
WO2018013689A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
CN110073002A (en) | 2016-10-17 | 2019-07-30 | 合成基因组公司 | Recombinant virus replicates subsystem and application thereof |
WO2018106615A2 (en) | 2016-12-05 | 2018-06-14 | Synthetic Genomics, Inc. | Compositions and methods for enhancing gene expression |
WO2018165142A1 (en) | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
EA201992780A1 (en) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR TREATMENT OF CANCER, INFLAMMATORY DISEASES, RAS OPATIAS AND FIBROUS DISEASE |
EP3644999B1 (en) | 2017-06-30 | 2022-12-14 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
AU2018345647A1 (en) | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
KR20200061363A (en) | 2017-10-04 | 2020-06-02 | 셀진 코포레이션 | Cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl ]-1-methylcyclohexane-1-carboxamide production process |
CN111565736B (en) * | 2017-10-11 | 2024-03-08 | 礼蓝美国股份有限公司 | Pig G-CSF variants and uses thereof |
BR112020009055A2 (en) | 2017-11-06 | 2020-11-03 | Rapt Therapeutics, Inc. | chemokine receptor modulators for positive cancer treatment for epstein-Barr virus |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
EA202091513A1 (en) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION |
EA202091516A1 (en) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV) |
US11083786B2 (en) | 2018-01-19 | 2021-08-10 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
WO2020234742A1 (en) | 2019-05-20 | 2020-11-26 | Lupin Limited | Granulocyte colony stimulating factor purification |
EP4168414A1 (en) | 2020-06-18 | 2023-04-26 | Shy Therapeutics LLC | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
WO2023201282A1 (en) | 2022-04-14 | 2023-10-19 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4358535A (en) * | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
US4394443A (en) * | 1980-12-18 | 1983-07-19 | Yale University | Method for cloning genes |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
IE56026B1 (en) * | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
JPS6023777A (en) * | 1983-07-15 | 1985-02-06 | 鶴海合成炉材株式会社 | Melting holding manual furnace for low melting-point metal |
US4710473A (en) * | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
JPS60206066A (en) * | 1984-03-29 | 1985-10-17 | Toshiba Corp | Solid-state image pickup device |
JPS60209638A (en) * | 1984-04-03 | 1985-10-22 | Diesel Kiki Co Ltd | Electronic governor for diesel engine |
JPS60217150A (en) * | 1984-04-13 | 1985-10-30 | マツダ株式会社 | Coated fiber reinforced urethane molded shape |
JPS61227526A (en) * | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | Novel csf and method of collecting same |
WO1986004605A1 (en) * | 1985-02-08 | 1986-08-14 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
JPH0615477B2 (en) * | 1985-02-08 | 1994-03-02 | 中外製薬株式会社 | Anti-infective agent |
JPH01110629A (en) * | 1985-04-05 | 1989-04-27 | Chugai Pharmaceut Co Ltd | Phylactic |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (en) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | DNA encoding multipotent granulocyte colony stimulating factor |
JPS62236497A (en) * | 1985-09-17 | 1987-10-16 | Chugai Pharmaceut Co Ltd | Novel glycoprotein and production thereof |
ATE67517T1 (en) * | 1985-09-30 | 1991-10-15 | Chugai Pharmaceutical Co Ltd | HUMAN GRANULOCYTE COLONY STIMULATING FACTOR. |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
JP2976258B2 (en) * | 1992-07-07 | 1999-11-10 | 株式会社名機製作所 | Hot press insulation mounting structure |
-
1986
- 1986-03-03 US US06/835,548 patent/US4810643A/en not_active Expired - Lifetime
- 1986-08-22 WO PCT/US1986/001708 patent/WO1987001132A1/en active IP Right Grant
- 1986-08-22 GR GR862185A patent/GR862185B/en unknown
- 1986-08-22 IL IL79805A patent/IL79805A/en not_active IP Right Cessation
- 1986-08-22 AU AU63346/86A patent/AU6334686A/en not_active Abandoned
- 1986-08-22 EP EP86905530A patent/EP0237545B2/en not_active Expired - Lifetime
- 1986-08-22 SG SG1996004322A patent/SG48964A1/en unknown
- 1986-08-22 NZ NZ217334A patent/NZ217334A/en unknown
- 1986-08-22 KR KR870700352A patent/KR880700071A/en not_active Application Discontinuation
- 1986-08-22 DE DE3650788T patent/DE3650788T2/en not_active Expired - Lifetime
- 1986-08-22 PT PT83242A patent/PT83242B/en unknown
- 1986-08-22 AT AT00101091T patent/ATE332375T1/en not_active IP Right Cessation
- 1986-08-23 ES ES8601318A patent/ES2001883A6/en not_active Expired
- 1986-08-23 CN CN86106234A patent/CN1020924C/en not_active Expired - Lifetime
- 1986-08-25 CA CA000516737A patent/CA1341537C/en active Active
-
1987
- 1987-04-16 FI FI871700A patent/FI105191B/en not_active IP Right Cessation
- 1987-04-22 NO NO871679A patent/NO303544B1/en not_active IP Right Cessation
- 1987-04-22 DK DK198702044A patent/DK174980B1/en not_active IP Right Cessation
-
1989
- 1989-05-02 JP JP1113512A patent/JP2527365B2/en not_active Expired - Lifetime
- 1989-05-02 JP JP1113513A patent/JPH0231675A/en active Granted
-
1991
- 1991-05-17 JP JP3141402A patent/JP2660178B2/en not_active Expired - Lifetime
- 1991-09-27 JP JP3277149A patent/JP2660179B2/en not_active Expired - Lifetime
-
1992
- 1992-03-26 SG SG358/92A patent/SG35892G/en unknown
- 1992-06-18 MX MX9202992A patent/MX9202992A/en unknown
- 1992-10-21 SA SA92130186A patent/SA92130186B1/en unknown
- 1992-11-06 CY CY1642A patent/CY1642A/en unknown
-
1993
- 1993-07-01 NL NL930127C patent/NL930127I1/en unknown
-
1995
- 1995-05-26 US US08/452,135 patent/US5582823A/en not_active Expired - Lifetime
- 1995-06-02 US US08/459,298 patent/US5580755A/en not_active Expired - Lifetime
-
1996
- 1996-03-12 JP JP8055077A patent/JP2718426B2/en not_active Expired - Lifetime
- 1996-07-11 US US08/678,692 patent/US5676941A/en not_active Expired - Fee Related
- 1996-07-15 US US08/679,897 patent/US5830705A/en not_active Expired - Fee Related
-
1997
- 1997-02-18 JP JP9033849A patent/JP2952203B2/en not_active Expired - Lifetime
-
1998
- 1998-05-11 NO NO19982132A patent/NO314902B1/en active Protection Beyond IP Right Term
-
1999
- 1999-02-12 JP JP11034848A patent/JP3115561B2/en not_active Expired - Lifetime
-
2000
- 2000-01-04 FI FI20000014A patent/FI107540B/en not_active IP Right Cessation
- 2000-03-08 JP JP2000064219A patent/JP2000279185A/en active Pending
- 2000-12-12 HK HK00107970A patent/HK1029600A1/en not_active IP Right Cessation
-
2001
- 2001-02-21 FI FI20010334A patent/FI110576B/en not_active IP Right Cessation
-
2002
- 2002-03-28 JP JP2002092947A patent/JP2002315578A/en active Pending
-
2003
- 2003-05-19 NO NO20032250A patent/NO318755B1/en not_active IP Right Cessation
- 2003-11-13 NO NO2003008C patent/NO2003008I1/en unknown
- 2003-11-26 JP JP2003394905A patent/JP2004041242A/en not_active Withdrawn
- 2003-12-09 NO NO2003010C patent/NO2003010I2/en not_active IP Right Cessation
-
2004
- 2004-12-17 NO NO20045548A patent/NO20045548L/en unknown
-
2006
- 2006-01-11 JP JP2006004052A patent/JP2006101889A/en active Pending
Non-Patent Citations (8)
Title |
---|
Blood, (New York) (NICOLA et al) issued September 1979 "Separation of Functionally Distinct Human Granulocytemacrophage Colony-Stiumlating Factors", see pages 614-627. * |
J. Biological Chemistry, (Bethesda, Md.), (HEWICK et al), Volume 256, issued 10 August 1981, "A Gas-Liquid Solid Phase Peptide and Protein Sequenator", see pages 7990-7997. * |
Molecular and Cellular Biology, (Washington, D.C. USA), (OKAYAMA et al), Volume 3, issued February, 1983, "A cDNA Cloning Vector that Permits Expression of cDNA Inserts in Mammalian Cells", see pages 280-289. * |
Nature, (London, England), (GOUGH et al), Volume 309, issued June 1984, "Molecular Cloning of cDNA Encoding a Murine Haematopoietic Growth Regulator, Granulocyte-Macrophage Colony Stimulating Factor", see pages 763-767. * |
Proceedings National Academy of Sciences (Washington, D.C., USA), (DALBADIE-McFARLAND et al), Volume 79, issued November, 1982, "Oligonucleotide-Directed Mutagenesis as a General and Powerful Method for Studies of Protein Function", see pages 6409-6413. * |
Proceedings National Academy of Sciences (Washington, D.C., USA), (WELTE et al), Volume 82, issued March, 1985, "Purification and Biochemical Characterization of Human Pluripotent Hematopoietic Colonystimulating Factor", see pages 1526-1530. * |
Proceedings National Academy of Sciences, (Washington, D.C. USA), (NICOLA et al), Volume 81, issued June 1984, "Binding of the Differentiation-Inducer, Granulocyte-Colony-Stimulating Factor, to Responsive but not Unresponsive Leukemic Cell Lines", see pages 3765-1769. * |
Proceedings National Academy of Sciences, (Washington, D.C., USA), (LERNER et al), Volume 78, issued June, 1981, "Chemically Synthesized Peptides Predicted from the Nucleotide Sequence of the Hepatitis B Virus Genome Elicit Antibodies Reactive with the Native Envelope Protein of Dane Particles", see pages 3403-3407. * |
Cited By (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215126A1 (en) * | 1985-02-08 | 1987-03-25 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
EP0215126B1 (en) * | 1985-02-08 | 1991-07-31 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
EP0243153A2 (en) * | 1986-04-22 | 1987-10-28 | Immunex Corporation | Human G-CSF protein expression |
EP0243153A3 (en) * | 1986-04-22 | 1988-01-13 | Immunex Corporation | Human g-csf protein expression |
EP0256843A1 (en) * | 1986-08-11 | 1988-02-24 | Cetus Corporation | Expression of g-csf and muteins thereof and their use |
WO1988001297A1 (en) * | 1986-08-11 | 1988-02-25 | Cetus Corporation | Expression of g-csf and muteins thereof |
US5214132A (en) * | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US5194592A (en) * | 1986-12-23 | 1993-03-16 | Kyowa Hakko Kogyo Co. Ltd. | Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor |
EP0272703A1 (en) | 1986-12-23 | 1988-06-29 | Kyowa Hakko Kogyo Co., Ltd. | Novel polypeptide |
GB2213821A (en) * | 1987-12-23 | 1989-08-23 | British Bio Technology | Synthetic gene |
GB2213821B (en) * | 1987-12-23 | 1992-01-02 | British Bio Technology | Synthetic human granulocyte colony stimulating factor gene |
US5599690A (en) * | 1988-02-01 | 1997-02-04 | Amgen Inc. | Control of norleucine incorporation into recombinant proteins |
EP0331186A2 (en) * | 1988-03-04 | 1989-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Monoclonal antibody selectively binding to novel g-csf derivative |
EP0331186A3 (en) * | 1988-03-04 | 1990-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Monoclonal antibody selectively binding to novel g-csf derivative |
EP0719860A1 (en) * | 1988-05-13 | 1996-07-03 | Amgen Inc. | Compositions and method for treating or preventing infections in animals |
EP0422872A2 (en) * | 1989-10-12 | 1991-04-17 | Gene-Trak Systems | Nucleic acid probes and methods for detecting fungi |
EP0422872A3 (en) * | 1989-10-12 | 1994-01-05 | Gene Trak Systems | |
WO1994017185A1 (en) * | 1993-01-28 | 1994-08-04 | Amgen Inc. | G-csf analog compositions and methods |
US8058398B2 (en) | 1993-01-28 | 2011-11-15 | Amgen Inc. | Modified G-CSF polypeptide |
EP0612846A1 (en) * | 1993-01-28 | 1994-08-31 | Amgen Inc. | G-CSF analog compositions and methods |
US5790421A (en) * | 1993-01-28 | 1998-08-04 | Amgen Inc. | Computer apparatus for expressing a three dimensional structure of a G-CSF molecule or analogs thereof |
EP0974655A2 (en) * | 1993-01-28 | 2000-01-26 | Amgen Inc. | G-CSF analog compositions and methods |
US6261550B1 (en) | 1993-01-28 | 2001-07-17 | Amgen Inc. | G-CSF hybrid molecules and pharmaceutical compositions |
EP0974655A3 (en) * | 1993-01-28 | 2001-10-24 | Amgen Inc., | G-CSF analog compositions and methods |
EP2345724A1 (en) * | 1993-01-28 | 2011-07-20 | Amgen Inc. | G-CSF analog compositions and methods |
US6632426B2 (en) | 1993-01-28 | 2003-10-14 | Amgen Inc. | G-CSF analog compositions and methods |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
EP1482045A2 (en) * | 1993-01-28 | 2004-12-01 | Amgen Inc. | G-CSF analog compositions and methods |
EP1482045A3 (en) * | 1993-01-28 | 2004-12-29 | Amgen Inc. | G-CSF analog compositions and methods |
AU2011201971B2 (en) * | 1993-01-28 | 2011-12-01 | Amgen Inc. | G-CSF analog compositions |
US7381804B2 (en) | 1993-01-28 | 2008-06-03 | Amgen Inc. | G-CSF analog compositions and methods |
US7090835B2 (en) | 1994-10-12 | 2006-08-15 | Amgen, Inc. | N-terminally chemically modified protein compositions and methods |
US7662933B2 (en) | 1994-10-12 | 2010-02-16 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6956027B2 (en) | 1994-10-12 | 2005-10-18 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US8748392B2 (en) | 1997-07-14 | 2014-06-10 | Bolder Biotechnology Inc. | Methods of treatment using cysteine variants of interleukin-11 |
US8133480B2 (en) | 1997-07-14 | 2012-03-13 | Bolder Biotechnology, Inc. | Cysteine variants of interleukin-11 |
US7964184B2 (en) | 1997-07-14 | 2011-06-21 | Bolder Biotechnology, Inc. | Cysteine variants of interferon-gamma |
US8618256B2 (en) | 1997-07-14 | 2013-12-31 | Bolder Biotechnology | Cysteine variants of interferon gamma |
US8148500B2 (en) | 1997-07-14 | 2012-04-03 | Bolder Biotechnology, Inc. | Method of preparing cysteine mutants of human recombinant GM-CSF |
US7959909B2 (en) | 1997-07-14 | 2011-06-14 | Bolder Biotechnology, Inc. | Cysteine variants of interferon gamma |
US10329337B2 (en) | 1997-07-14 | 2019-06-25 | Bolder Biotechnology, Inc. | Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11 |
US8859497B2 (en) | 1997-07-14 | 2014-10-14 | Bolder Biotechnology, Inc. | Method of treatment using cysteine mutants of beta interferon |
US9637530B2 (en) | 1997-07-14 | 2017-05-02 | Bolder Biotechnology, Inc. | Methods of preparing cysteine variants of human recombinant IL-11 |
US8101188B2 (en) | 1997-10-02 | 2012-01-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
US8957023B2 (en) | 1999-01-14 | 2015-02-17 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
US7696153B2 (en) | 2000-01-10 | 2010-04-13 | Maxygen, Inc. | G-CSF conjugates |
WO2002066051A1 (en) | 2001-02-22 | 2002-08-29 | Didier Pourquier | Use of the g-csf as adjuvant treatment in connective tissue recontruction |
WO2004001056A1 (en) * | 2002-06-24 | 2003-12-31 | Dr. Reddy's Laboratories Ltd. | Process for preparing g-csf |
US7884069B2 (en) | 2002-12-31 | 2011-02-08 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoeitic growth factors |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
EP2311483A1 (en) | 2002-12-31 | 2011-04-20 | SYGNIS Bioscience GmbH & Co KG | GCSF for use in treating a neurological disease with pathophysiological mechanisms involving ischemia or hypoxia |
US8053407B2 (en) | 2002-12-31 | 2011-11-08 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoeitic growth factors |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US8071543B2 (en) | 2002-12-31 | 2011-12-06 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoeitic growth factors |
EP2186525A2 (en) | 2002-12-31 | 2010-05-19 | SYGNIS Bioscience GmbH & Co KG | G-CSF for use in the treatment of Parkinson's disease |
EP2295069A1 (en) | 2004-06-30 | 2011-03-16 | Sygnis Bioscience GmbH & Co. KG | Treatment of neurological disorders with haematopoietic growth factors |
US7655766B2 (en) | 2005-06-01 | 2010-02-02 | Carsten Germansen | Compositions comprising positional isomers of PEGylated G-CSF |
US9512457B2 (en) | 2005-06-30 | 2016-12-06 | Octapharma Ag | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US9796986B2 (en) | 2005-06-30 | 2017-10-24 | Octapharma Ag | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US9273325B2 (en) | 2005-06-30 | 2016-03-01 | Carola Schroeder | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US8871439B2 (en) | 2005-06-30 | 2014-10-28 | Octapharma Ag | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US9815879B2 (en) | 2005-07-15 | 2017-11-14 | Sandoz Ag | Method for the purification of G-CSF |
US10844103B2 (en) | 2005-07-15 | 2020-11-24 | Mylan Pharmaceuticals Inc. | Method for the purification of G-CSF |
EP1904522B2 (en) † | 2005-07-15 | 2020-05-27 | Mylan Pharmaceuticals Inc. | Method for the purification of g-csf |
EP2058326A1 (en) | 2005-07-15 | 2009-05-13 | Bioceuticals Arzneimittel AG | Method for the purificaiton of G-CSF |
DE202007018618U1 (en) | 2006-03-01 | 2008-12-11 | Bioceuticals Arzneimittel Ag | G-CSF liquid formulation |
EP2098243A1 (en) | 2006-03-01 | 2009-09-09 | Bioceuticals Arzneimittel AG | G-CSF liquid formulation |
WO2008096370A2 (en) * | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
WO2008096370A3 (en) * | 2007-02-05 | 2008-12-31 | Natco Pharma Ltd | An efficient and novel purification method of recombinant hg-csf |
US8946161B2 (en) | 2007-08-27 | 2015-02-03 | Ratiopharm Gmbh | Method of treatment using stable liquid formulation of G-CSF |
DE202008017456U1 (en) | 2007-08-27 | 2009-08-27 | Biogenerix Ag | Liquid formulation of G-CSF conjugates |
US8562967B2 (en) | 2007-08-27 | 2013-10-22 | Biogenerix Ag | Stable liquid formulations of G-CSF |
US9468685B2 (en) | 2007-08-27 | 2016-10-18 | Ratiopharm Gmbh | Methods of preparing a liquid formulation of G-CSF |
EP2578235A2 (en) | 2007-08-27 | 2013-04-10 | BioGeneriX AG | Liquid formulation of G-CSF conjugate |
US9155780B2 (en) | 2009-02-11 | 2015-10-13 | Yeda Research And Development Co. Ltd. | Short beta-defensin-derived peptides |
US9567371B2 (en) | 2009-02-11 | 2017-02-14 | Yeda Research And Development Co. Ltd. | Short beta-defensin-derived peptides |
EP2341061A1 (en) | 2009-12-31 | 2011-07-06 | Sanovel Ilac Sanayi ve Ticaret A.S. | A novel process for preparing G-CSF (granulocyte colony stimulating factor) |
EP3578205A1 (en) * | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
EP3517621A1 (en) | 2012-03-19 | 2019-07-31 | Richter Gedeon Nyrt. | Method for the production of polypeptides |
US9416164B2 (en) | 2012-03-19 | 2016-08-16 | Richter Gedeon Nyrt. | Method for the production of polypeptides |
KR101933753B1 (en) | 2012-03-19 | 2018-12-28 | 리히터 게데온 닐트. | Methods for refolding g-csf from inclusion bodies |
WO2013068603A3 (en) * | 2012-03-19 | 2013-08-29 | Richter Gedeon Nyrt. | Methods for refolding g-csf from inclusion bodies |
US9458207B2 (en) | 2012-03-19 | 2016-10-04 | Richter Gedeon Nyrt. | Methods for refolding G-CSF from inclusion bodies |
WO2013068603A2 (en) * | 2012-03-19 | 2013-05-16 | Richter Gedeon Nyrt. | Methods for refolding g-csf from inclusion bodies |
WO2013068602A2 (en) | 2012-03-19 | 2013-05-16 | Richter Gedeon Nyrt. | Method for the production of polypeptides |
EP3070099A1 (en) | 2015-03-16 | 2016-09-21 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for preparing granulocyte colony stimulating factor (g-csf) |
WO2016146629A1 (en) | 2015-03-16 | 2016-09-22 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for preparing g-csf (granulocyte colony stimulating factor) |
WO2017067958A1 (en) * | 2015-10-19 | 2017-04-27 | Sandoz Ag | Improved coding sequence for human g-csf |
US10947287B2 (en) | 2015-10-19 | 2021-03-16 | Sandoz Ag | DNA coding sequence for human G-CSF |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0237545B2 (en) | Production of pluripotent granulocyte colony-stimulating factor | |
US4999291A (en) | Production of human pluripotent granulocyte colony-stimulating factor | |
US6716606B2 (en) | Production of pluripotent granulocyte colony-stimulating factor | |
EP1018552B1 (en) | Production of pluripotent granulocyte colony-stimulating factor | |
AU727724B2 (en) | Production of pluripotent granulocyte colony-stimulating factor | |
AU769969B2 (en) | Production of pluripotent granulocyte colony-stimulating factor | |
AU2004202013A1 (en) | Production of pluripotent granulocyte colony-stimulating factor | |
DK175551B1 (en) | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders | |
BG63065B2 (en) | Analogues of pluripotent granulocytic colony-stimulating factor | |
BG63285B2 (en) | Production of human pluripotent granulocytic colony-stimulation factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP KR NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1986905530 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 871700 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1986905530 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1986905530 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20000014 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: 871700 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20010334 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: 20000014 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: 20010334 Country of ref document: FI |